In the original article, there was error in [Table 1](#T1){ref-type="table"} as published. The probiotic efficacy for Emara 2014 and Francavilla 2014 reported a significant increase instead of a non-significant increase.

###### 

Selected clinical trials using *Lactobacillus reuteri* for *H. pylori* eradication treatment.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Treatment**                                                                                                     **Probiotic(s)**                                                                                                                                                                    **Eradication rate**       **Probiotic efficacy**                                                                                                               **References**
  ----------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------- ------------------------------------------------------------------------------------------------------------------------------------ ---------------------------
  Triple therapy, Omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, 14 d                                    *L. reuteri* ATCC PTA 6475,\                                                                                                                                                        74.3% (26/35)\             Non-significant increase of eradication rate with improved GSRS score and reduction of side effects (taste disorder, diarrhea)       Emara et al., [@B3]
                                                                                                                    *L. reuteri* DSM 17938, 14 d during therapy + further 14 d, [Control]{.ul}                                                                                                          [65.7% (23/35)]{.ul}                                                                                                                                            

  Three-phase study; pre-eradication (1--28 d), eradication (29--35 d), follow-up (36--96 d), Triple therapy        *L. reuteri* ATCC PTA 6475,\                                                                                                                                                        75% (37/50)\               Non-significant increase of eradication rate but no difference in GSRS score                                                         Francavilla et al., [@B5]
                                                                                                                    *L. reuteri* DSM 17938, [Control]{.ul}                                                                                                                                              [65.9% (33/50)]{.ul}                                                                                                                                            

  Pantoprazole 20 mg, 8 weeks                                                                                       *L. reuteri*, 8 weeks                                                                                                                                                               14.2% (3/21)               Good tolerability with no side effects                                                                                               Dore et al., [@B1]

  Levofloxacin 500 mg, esomeprazole 20 mg, amoxicillin 1 g, 7 d                                                     *L. reuteri*, during therapy + further 7 d [Control]{.ul}                                                                                                                           80% (36/45)\               Significantly increase of eradication rates and reduction of side effects (Nausea, diarrhea)                                         Ojetti et al., [@B8]
                                                                                                                                                                                                                                                                                                        [62.2% (28/45)]{.ul}                                                                                                                                            

  Omeprazole 1 mg/kg, amoxicillin 50 mg/kg, clarithromycin15 mg/kg, 7 d                                             *L. plantarum, L. reuteri, L. casei* subsp*. rhamnosus, B. infantis, and B. longum, L. acidophilus, L. salivarius, S. thermophilus, L. sporogenes*, during therapy [Control]{.ul}   82.2% (30/34)\             Non-significant increase of eradication rates; significant reduction of side effects (epigastric pain, nausea, vomiting, diarrhea)   Tolone et al., [@B10]
                                                                                                                                                                                                                                                                                                        [76.4% (26/34)]{.ul}                                                                                                                                            

  Pantoprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, [Triple therapy, 7 d Sequential regimen, 10 d]{.ul}   *L. reuteri* ATCC55730, during therapy + further 7 or 10 d                                                                                                                          [63% (52/83)]{.ul}\        Significantly higher eradication rate and reduction of side effects in sequential regimen                                            Efrati et al., [@B2]
                                                                                                                                                                                                                                                                                                        [88% (73/83)]{.ul}                                                                                                                                              

  Sequential therapy (Details not describe)                                                                         *L. reuteri* ATCC55730, 8 weeks [Control]{.ul}                                                                                                                                      33.8 ± 15% (33)\           Significant decrease in Gastrointestinal Symptom                                                                                     Francavilla et al., [@B4]
                                                                                                                                                                                                                                                                                                        [35.8 ± 15.5% (33)]{.ul}                                                                                                                                        

  Triple therapy (Details not describe)                                                                             *L. reuteri*, 7 d [Control]{.ul}                                                                                                                                                    63%\                       Lowest incidence of side-effects                                                                                                     Scaccianoce et al., [@B9]
                                                                                                                                                                                                                                                                                                        [53%]{.ul}                                                                                                                                                      

  No drug                                                                                                           *L. reuteri* SD2112, 8 weeks                                                                                                                                                        69.7 ± 4% (33)             Significant reduction of ^13^C-UBT                                                                                                   Imase et al., [@B6]

  Omeprazole 1 mg/kg, amoxicillin 50 mg/kg, clarithromycin15 mg/kg, sequential therapy, 10 d                        *L. reuteri* ATCC55730 (SD2112) [Control]{.ul}                                                                                                                                      85% (17/20)\               Significant reduction of GSRS score                                                                                                  Lionetti et al., [@B7]
                                                                                                                                                                                                                                                                                                        [80% (16/20)]{.ul}                                                                                                                                              
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

*GSRS, Gastrointestinal Symptom Rating Scale; ^13^C-UBT; ^13^C Urea Breath Test*.

Additionally, the reference for "Francavilla et al., 2008" in [Table 1](#T1){ref-type="table"} was incorrectly written as "Francavilla, R., Lionetti, E., and Cavallo, L. (2008). Sequential treatment for Helicobacter pylori eradication in children. *Gut* 57:1178." It should be "Francavilla, R., Lionetti, E., Castellaneta, S. P., Magistà, A. M., Maurogiovanni, G., Bucci, N., et al. (2008). Inhibition of *Helicobacter pylori* infection in humans by *Lactobacillus* reuteri ATCC 55730 and effect on eradication therapy: a pilot study. *Helicobacter* 13, 127--134. doi: [10.1111/j.1523-5378.2008.00593.x](https://doi.org/10.1111/j.1523-5378.2008.00593.x)".

The corrected [Table 1](#T1){ref-type="table"} and Reference appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

[^1]: Edited and reviewed by: Fabio Minervini, University of Bari Aldo Moro, Italy

[^2]: This article was submitted to Food Microbiology, a section of the journal Frontiers in Microbiology
